DiaMedica Therapeutics Inc. (DMAC) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $9.25 (-2.84% 1D, market cap $513.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DMAC ranks #437 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMAC carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INDP (Indaptus Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $513.0M) and ARVN (Arvinas Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -32.1%, cap $516.6M). Among the 5-stock peer group, DMAC leads on earnings multiple (N/A) while ARVN leads on capital efficiency (-32.1% ROIC).
Per DMAC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401040), DiaMedica Therapeutics Inc. generated $0 in revenue, -$32.8M in net income, and -$29.1M in free cash flow against $61.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While DMAC currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.67) and Max Pain ($9.71) forces dealer call-delta covering toward $10.94.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
DiaMedica Therapeutics Inc. (DMAC) dropped -2.84% to $9.25, trading at 77% of its 52-week range ($5.24 – $10.42). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
MINNEAPOLIS, October 22, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic s
Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-EstimationInterim Analysis Results Expected in Q1 2027
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DMAC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DMAC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, DiaMedica Therapeutics Inc. (DMAC) ranks #437 by composite RQD confidence (44/100, grade D) and #445 by equity capitalization ($513.4M). Within this direct 5-issuer industry benchmark cohort, DMAC leads on earnings valuation at N/A trailing P/E, while ARVN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with DMAC at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DMAC
ACTIVE
DiaMedica Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -2.84% | $513.4M | Benchmark Subject |
| INDP Indaptus Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -7.48% | $513.0M | /indp-vs-dmac → |
| ARVN Arvinas Inc. | E | 23/100 | — | — | -32.1% | -0.51% | $516.6M | /arvn-vs-dmac → |
| OCS Oculis Holding AG | D | 47/100 | — | — | — | +0.24% | $507.5M | /ocs-vs-dmac → |
| AQST Aquestive Therapeutics Inc. | E | 18/100 | — | 58.3% | -35.0% | -3.71% | $507.1M | /aqst-vs-dmac → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), DiaMedica Therapeutics Inc. (DMAC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$32.8M, operating cash flow of -$29.1M, and free cash flow of -$29.1M (-31.7% YoY). On the balance sheet, DMAC closed FY2025 with $61.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$32.8M | -$29.1M | -$29.1M | $61.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$24.4M | -$22.1M | -$22.1M | $46.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$19.4M | -$18.7M | -$18.7M | — | — |
As of 2026-11-02, DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $9.25 (-2.84% 1D, market cap $513.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DMAC ranks #437 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMAC carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INDP (Indaptus Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $513.0M) and ARVN (Arvinas Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -32.1%, cap $516.6M). Among the 5-stock peer group, DMAC leads on earnings multiple (N/A) while ARVN leads on capital efficiency (-32.1% ROIC).
Per DMAC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401040), DiaMedica Therapeutics Inc. generated $0 in revenue, -$32.8M in net income, and -$29.1M in free cash flow against $61.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DMAC last traded at $9.25 (-2.84% on volume of 174,657 shares), positioning the stock +20.60% above its 50-day simple moving average ($7.67) and +30.10% above its 200-day simple moving average ($7.11). Across its 52-week range of $5.24 to $10.42, DMAC sits at the 77.4% percentile with a 14-day RSI of 65.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.09 to $10.41).
Why DMAC Stock dropped -2.84% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, DMAC scores 44 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows. Fundamental Cash Engine scores 7 of 20, reflecting an ROIC of -35% and an FCF yield of -5.67%, which signals that the business is currently consuming rather than generating cash. Whale 13F Flow scores 15 of 20, indicating institutional accumulation and options positioning that is comparatively the strongest pillar. Insider Conviction scores 3 of 20 on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar in the rating. Macro Regime Fit scores 9 of 20 with a Beta of 1.0 and noted sector sensitivity. Forensic Balance Sheet scores 10 of 20, reflecting an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5.
For a prospective investor, the practical implication is that the upside case rests on institutional interest and the pipeline catalysts in the news wire rather than on current cash generation or insider conviction. Valuation cannot be anchored to earnings because P/E and EV/EBITDA are not available in source data, and the company reports zero revenue and negative operating income in each reported period. The rating frames the stock as a higher-risk, catalyst-dependent name whose near-term direction depends on whether trial milestones translate into sustained capital inflows.
Per the recent news and catalysts section, the wire contains six items, each tied to DMAC. The most significant risk-flagged item is a report that DiaMedica reached a patient enrollment milestone for a Phase 2/3 trial of DM199 in acute ischemic stroke, marked RED under the RISK WATCH label. Other items, labeled MARKET WIRE with YELLOW status, include reports that the company reached 200 patients in its pivotal stroke trial, a webinar scheduled to present early results from two groups in a pregnancy trial on Nov. 24, and general seasonal return and price-action commentary from aggregator sources. The news wire contains no proprietary signals, and the Butterfly Supply-Chain Graph reports no supply-chain links, per its section.
Real-time company headlines, analyst actions, and sector developments for DiaMedica Therapeutics Inc. (DMAC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering DiaMedica Therapeutics Inc. (DMAC) market action, institutional positioning, and fundamental catalysts.
Welcome to the DMAC (DiaMedica Therapeutics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on DMAC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless DiaMedica Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on DMAC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $9.52 (52-wk range $5.24 - $10.42), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).